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Abstract Breast cancer affected 1.7 million people worldwide in 2012 and accounts for approximately 23.3 % of all
cancers diagnosed in women. The disease is characterized by a genetic mutation, either inherited or resulting from envi-
ronmental factors, that causes uncontrollable cellular growth of breast tissue or adjacent tissues. Current means of diag-
nosing this disease depend on the individual analyzing the results from bulky, highly technical, and expensive equipment
that is not globally accessible. As a result, patients can go undiagnosed due to a lack of available equipment or be over-
diagnosed due to human error. This review attempts to highlight current means of diagnosing breast cancer and critically
analyze their effectiveness and usefulness in terms of patient survival. An alternative means based on microfluidics
biomarker detection is then presented. This method can be considered as a primary screening tool for diagnosing breast
cancer based on its robustness, high throughput, low energy requirements, and accessibility to the general public.
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DSB Double strand break
ER? Estrogen receptor positive
ER- Estrogen receptor negative
PR? Progesterone positive
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SLNB Sentinel lymph node biopsy
AJCC American Joint Committee on Cancer
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1 Introduction
Consider how illnesses are presently diagnosed. A patient
develops some symptoms, they visit their doctor, and their
doctor runs tests to identify the ailment. Next, either the
doctor figures out the problem and prescribes some treat-
ments, or the patient is sent to a specialist for further tests.
At the visit to the specialist, more tests are conducted until
a diagnosis is reached; then, the patient is treated based on
this diagnosis. For a majority of illnesses, this method of
diagnosing a patient is generally successful; however, in
the case of cancer, once symptoms begin to manifest, it
may already be too late.
Age, lifestyle, genetics, nutrition, and stress all play
their respective roles in the development of cancers [1, 2].
As a person ages, becomes more sedentary [3–6] and gains
excess weight [7–9], the rate of diagnosis of serious life-
threatening diseases such as cancer is amplified [10–13].
The Centers for Disease Control and Prevention (CDC)
report that malignant neoplasms are second only to heart
diseases as a worldwide cause of deaths [14]. Globally, the
proportion of deaths attributed to malignant neoplasms has
risen from 12.49 % of all deaths in 2002, when they ranked
third in worldwide causes of death, to 23.3 % today [14,
15]. The development of a malignant neoplasm is a com-
plex process and depends on many factors, such as genetic
susceptibility, damage to the DNA, and even the location in
the body where the neoplasm starts. As the malignant
neoplasm advances into its later stages, survival rates drop
exponentially [16–19]. Preventative measures such as
exercising, eating a healthy diet, avoiding stress, and
managing weight can be taken to reduce the risk of
developing malignant neoplasms; however, these measures
do not eliminate the effect of genetic predispositions or
mutations that may occur during an individual’s life. Fig-
ure 1 shows how an error can cause cancer due to a double-
strand break (DSB) in the DNA.
In many cancer cases, an error such as the example in
Fig. 1 can lead to an extremely detrimental state for a
patient. However, early detection can play a major role in
patient survival, especially in cases involving breast can-
cer. The patient survival rate drops exponentially as the
stages of cancer progress. Patients’ survival rates go down
from a 100 % 5-year survival after first diagnosis in stage
one to 93 % in stage two, 72 % in stage three, and 22 % in
stage four [20]. Therefore, the key to surviving malignant
neoplasms is the early detection when preventative mea-
sures fail.
If we can reevaluate how we diagnose breast cancer and
develop a more proactive means of diagnosing the disease
before it develops into a serious condition rather than after
symptoms present themselves, we can take steps toward
making diagnostic medicine a much more effective tool for
doctors to use.
This review examines breast cancer, specifically the
biomarkers that aid in diagnosing the disease, the methods
currently associated with breast cancer detection, and the
reasons why microfluidics should be the first choice in
breast cancer detection to increase survival rates through
early detection.
2 Breast Cancer
Breast cancer is a category of malignant neoplasms that
occur in or around the breast tissue, and it is a type of
adenocarcinoma. This broad-scale classification encom-
passes many types of malignant neoplasms that can occur
in or around the breast tissue. Each type of neoplasm owns
specific type of disease with morphological, molecular, and
clinical variations [21]. Figure 2 shows how different
subtypes of breast cancers demonstrate different histolog-
ical characteristics.
The type of breast cancer that a person may develop is
dependent on the site of the neoplasm. The two most
common histological types of breast cancer are lobular and
ductal carcinomas (LCIS and DCIS, respectively) [21–23].
These two types account for 80–95 % of breast cancer
cases, while the remaining cases are rarer forms of breast
cancer such as acinic-cell carcinoma, adenoid cystic







Fig. 1 Schematic depicts a DSB leading to a genetic mutation. The
DSB causes damage to the DNA strand and leads to a cancerous state
(right). However, during correction, cellular death occurred, and a
cancerous state was avoided (left)
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carcinoma, comedo carcinoma, glycogen-rich clear cell
carcinoma, invasive apocrine carcinoma, invasive papillary
and micropapillary carcinomas, lipid-rich carcinoma,
medullary carcinoma, metaplastic carcinoma, mucinous
carcinoma, neuroendocrine carcinoma, sebaceous carci-
noma, and secretory carcinoma [22, 24]. In addition to
these variations of histological types of breast cancer, there
are hormonal variations in breast cancer such as estrogen
receptor-positive (ER?) or -negative (ER-), progesterone
receptor-positive (PR?) or -negative (PR-), and human
epidermal growth factor receptor 2-positive (HER2?) or -
negative (HER2-) cancers. These variations correspond to
different types of treatment that can be offered for breast
cancer.
2.1 Stages of Breast Cancer
Prior to treatment, an individual’s breast cancer is placed
within a ‘‘stage’’ ranging from 0 to IV. Staging breast
cancer helps to document the severity of the disease and
whether the malignant neoplasms have metastasized to
other parts of the body or remained in their local tissue. To
determine where the neoplasms are, a physician may
conduct a lymph node biopsy using a sentinel lymph node
biopsy (SLNB) or other tests such as a bone scan, com-
puted tomography (CT) scan, magnetic resonance imaging
(MRI), or positron emission tomography (PET) scan.
A SLNB involves the identification and removal of sentinel
lymph nodes as well as examination to determine whether
Fig. 2 Histological variance in breast cancer subtypes. Images from top left to bottom right: Invasive carcinoma of no special type, medullary,
tubular, cribriform, mucinous, and squamous metastatic breast cancer. Image taken from Breast: Ductal Carcinoma [117]
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neoplastic cells are present. A negative biopsy means that
neoplastic cells have not yet made their way to the sentinel
lymph nodes, whereas a positive biopsy indicates that
neoplastic cells are present in sentinel lymph nodes and
may potentially be present in regional lymph nodes and
other organs. Once the neoplastic cells are located in the
body, and it is determined whether they have metastasized,
the cancer is assigned a stage (Table 1). The staging of
breast cancer is based on the TNM classification of tumors,
as set by the American Joint Committee on Cancer (AJCC),
and is shown in Table 2 and explained in Table 1. The
TNM scale is used to differentiate the tumor size (T), the
lymph-node involvement (N), and whether any metasta-
sization has occurred (M).
Although the two most common breast cancers, DCIS
and LCIS, own different names, they originate from the
same place. Both begin in the terminal duct-lobular unit
Table 1 Breast cancer staging and explanations for each stage given [26]
Stage Explanation
0 Benign neoplasm, typically referred to as ‘carcinoma in situ’ (in original place). Usually found in ductal carcinoma in situ (DCIS),
lobular carcinoma in situ (LCIS) and pagets disease of the nipple
Non-invasive neoplasm, typically harmless and surgically removable
IA Malignant neoplasms that have not yet spread to other parts of the body or the lymph nodes. Diameter of 20 mm or less. Localized to
breast tissue
IB A malignant neoplasm that has begun to spread to lymph nodes in the breast tissue. The size of this neoplasm in lymph nodes is around
0.1 to 2.0 mm. Breasts may or may not show signs of neoplasms. If neoplasms do exist, size does not exceed 20 mm
IIA Malignant, invasive neoplasm that is either:
(1) Present in fewer than four axillary lymph nodes and has not been found in the breast
(2) Present in breast tissue, is less than 20 mm in size and has spread to less than four axillary lymph nodes, or
(3) Present in the breast tissue, has a diameter between 20 and 50 mm and has not yet spread to any axillary lymph nodes
IIB Malignant, invasive neoplasm that is either
(1) Present in the breast tissue, has a diameter between 20 and 50 mm and has spread to less than four axillary lymph nodes, or
(2) Present in the breast tissue, has a diameter greater than 50 mm, and has not yet spread to any axillary lymph nodes
IIIA Malignant, invasive neoplasm that is either
(1) Present in the breast tissue, has a diameter less than 20 mm and has spread to more than four lymph nodes, but is less than nine lymph
nodes, or
(2) Present in the breast tissue, has a diameter greater than 50 mm and neoplastic breast tissue is found in the lymph nodes, or
(3) Present in the breast tissue, has a diameter greater than 50 mm and neoplastic breast tissue is found in the lymph nodes under the arm
or at/around the breastbone
IIIB A malignant, invasive neoplasm of any size that has metastasized to the chest wall or breast skin, showing signs of swelling, ulcers,
inflammation, and has spread to less than nine regional lymph nodes
IIIC Malignant, invasive neoplasm that is either
1) Not present in the breast tissue or it is a neoplasm of any size in the breast tissue, has metastasized to the chest wall or breast skin,
shows signs of swelling, ulcers, and inflammation, and has spread to ten or more lymph nodes under the arm, or
2) Not present in the breast tissue or it is a neoplasm of any size in the breast tissue and has metastasized to the lymph nodes in the
collarbone region, or
3) Not present in the breast tissue or it is a neoplasm of any size in the breast tissue and has metastasized to lymph nodes under the arm or
in the breastbone region
IV Malignant invasive neoplasm that has metastasized to other parts of the body
Table 2 TNM Chart classifica-
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(TDLU), which connects the lobes to the ducts in the
breast. To differentiate DCIS from LCIS, the growth pat-
terns of the neoplastic tissue as well as the cytological
phenotypes of the tissue are examined. During examina-
tion, DCIS typically presents with calcification on a
mammogram, is typically unilateral (occurring in or on
only a single breast), and can form a myriad of different
structures under microscopic observation [21]. LCIS is
bilateral, dyscohesive under a microscope and is typically
not found on a mammogram [21] (Table 3).
3 Biomarkers
When a patient develops breast cancer, many physiological
changes occur within the body. Protein expressions and
levels are altered; genes become mutated, causing their
expression levels to change; microRNA (miRNA) expres-
sion levels change; and physical changes, such as lumps,
inflammation, and changes in skin, may also manifest
themselves [25–29]. Due to the complexity of breast cancer
and the way the human body operates, no single gene,
protein, or miRNA test has yet been developed that
definitively proves whether a patient has breast cancer.
Multiple tests are often required, and many biomarkers are
examined before any conclusions can be drawn about the
patient’s conditions and prognosis. Here, we will look at
different biomarkers involved with breast cancer, starting
with genetic markers.
3.1 Genetic Markers
Genetic markers are DNA mutations that can serve as
biomarkers to indicate the presence of a disease such as
breast cancer. Changes in regulation of protein expression,
loss of function of a cell, or even uncontrollable division
can occur if mutations in cellular DNA go uncorrected.
Here, some common genetic markers associated with
breast cancer are examined. Most markers addressed in this
Table 3 Explanation table for TNM rating for breast cancer based on the AJCC [27]
Rating Explanation
TX Tumor cannot be assessed
T0 No evidence of a tumor
Tis Carcinoma In Situ, typically associated with DCIS, LCIS or Pagets disease of the nipple
T1 Tumor diameter of 2 cm or less
T2 Tumor diameter greater than 2 cm but less than 5 cm
T3 Tumor diameter greater than 5 cm
T4 Tumor of any diameter invading the chest wall or skin
NX Unable to assess lymph nodes
N0(i ?) Small levels of cancer cells found in the underarm lymph nodes. Cancer cells less than 200 cells and smaller than 0.2 mm
N0(mol ?) Cancer cells not visible in the underarm lymph nodes, but detected via RT-PCR
N1mi Micrometastasis in 1 to 3 lymph nodes under the arm. Cancer cells have a diameter of 2 mm or less and at least 200 cancer cells
N1a Cancer spread to 1 to 3 lymph nodes under the arm; one area has cancer cells with a diameter of 2 mm or greater
N1b Spread to internal mammary lymph nodes, lymph nodes not enlarged. Detected via sentinel lymph node biopsy
N1c Both N1a and N1b
N2a Cancer found in 4 to 9 lymph nodes and one location has cancer cells larger than 2 mm
N2b Cancer spread to one or more internal mammary lymph nodes with enlargement in the nodes
N3a Either
Cancer in 10 or more axillary lymph nodes; one area has cancer cells with a diameter greater than 2 mm OR
Cancer spread to lymph nodes under clavicle; one area has cancer cells with a diameter greater than 2 mm
N3b Cancer found in axillary lymph nodes with a diameter greater than 2 mm and the internal mammary lymph nodes have enlarged
OR
Cancer spread to 4 or more axillary lymph nodes; cancer cells have a diameter of 2 mm or greater and are found on internal
mammary lymph nodes on a sentinel lymph node biopsy
MX Metastasis cannot be determined
M0 No distant cancer cells found on imaging equipment
M1 Cancer spread to distant organs
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section play their roles in the cell cycle; an illustration of
the cell cycle process is shown in Fig. 3.
3.1.1 BRCA1/2
The most common genetic marker examined for potential
breast cancer cases is the breast cancer susceptibility 1
(BRCA1) and 2 (BRCA2) genes. The BRCA1/2 genes are
responsible for creating the BRCA1 and BRCA2 proteins,
respectively. They are located on the long arm of chro-
mosome 17 at position 21 and the long arm of chromosome
13 at position 12.3, respectively. The BRCA1 protein is
responsible for DNA repair, signal transduction, and tumor
suppression [30–34]. BRCA1/2 proteins are also respon-
sible for repairing DSBs in the DNA sequence [30].
BRCA1/2 utilize two methods for DSB repairs: homolo-
gous recombination (HR) repair and non-homologous end-
joint repair (NHEJ) [30, 35, 36]. Currently, researchers
believe that tumorigenesis occurs when both the BRCA1
and BRCA2 genes are damaged or lost, leading to a lack of
proteins available to repair damaged DNA [37].
The BRCA1 gene belongs to a different family than the
BRCA2 gene. The BRCA1 gene belongs to the RING-type
zinc finger family (RNF), whereas the BRCA2 gene
belongs to the Fanconi anemia complementation group
(FANC). The BRCA1 protein is also reported to have the
ability to crosslink repair-damaged DNA strands [38].
Long and Walter suggest that BRCA1 modifies halted
replication at the DNA fork terminal in order to antagonize
a protein known as Ku70/Ku80 heterodimer (a protein
responsible for NHEJ repair of DNA strands) to prepare the
strands for binding with ubiquitylated FANCD2 (a group of
proteins in the FANC group, similar to BRCA2) [38]. This
suggests that BRCA1 attempts to call upon BRCA2 pro-
teins to help with DNA repair to suppress tumors. BRCA1
is able to repair DSB with HR repair via its C-terminal, as
depicted in Fig. 4. This motif of the protein is responsible
for interacting with RNA polymerase and CtIP to maintain
proper DNA structure [39]. Mutations in this region affect
BRCA10s ability to repair DNA and also hinder its ability
as a tumor suppressor.
3.1.2 PALB2
PALB2, a partner and localizer of BRCA2, is another gene
commonly associated with breast cancer. It codes for the
PALB2 proteins, whose function is tumor suppression.
This gene enlists the help of BRCA2 and RAD51 (dis-
cussed below) in DNA breaks via HR repair. PALB2
localizes and accumulates BRCA2 for DSB via HR repair
and is also responsible for localizing the BRCA2-RAD51
complex for DNA repair [40]. As the name suggests,
PALB2 enlists the support of BRCA2 (and BRCA1) to
create a BRCA1-PALB2-BRCA2 (BPB) complex that
provides HR repair [40]. PALB2 creates the BPB complex
by interacting with BRCA1 via its own N-terminal coiled-
coil domain and with BRCA2 via its own C-terminal
WD40 domain [41]. The PALB2 gene is located on the
short arm (p) of chromosome 16 at position 12.2. It is
suggested by Rahman et al. that PALB2 mutations may be
associated more with male breast cancer cases than with
female cases because of the involvement of BRCA2 [42];
however, this needs to be investigated further. Buisson
et al. found that, while traditionally it was thought that
BRCA2 and PALB2 regulated HR repair through regula-
tion of the RAD51 protein, PALB2 is also important for
Pol g (polymerase g) localization as well as DNA poly-
merization activity [41]. Mutations of PALB2 hinder its
ability to properly synthesize DNA, leading to breast
cancer due to mutations in the DNA. DSBs resulting from a
PALB2 mutation are not properly repaired, and the cells
can potentially enter a cancerous state [41].
3.1.3 BRIP1
BRCA1 interacting protein C-terminal helicase 1 (BRIP1)
is a gene that encodes for the BRIP1 protein. BRIP1,
located on the long arm of chromosome 17 at position 22.2,
interacts with BRCA1 to form a bound complex that
repairs DSBs in DNA to prevent damage and a potentially
cancerous state. This is similar to how PALB2 operates on





















Fig. 3 Cell cycle diagram [118]. Beginning at the G1 phase, cells
observe environmental conditions and await stimuli to begin the
replication process. During the G1 phase, when the conditions are
correct, the cells begin the replication process by synthesizing the
required RNAs and proteins. In the S phase, the chromosomal DNA is
replicated, and in the G2 phase, the cells prepare for mitosis. Mitosis
occurs in the M phase
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germline mutations that can induce cancer. The BRIP1
gene is also implicated in the Fanconi anemia (FA) DNA
repair pathway, a pathway responsible for repairing DSBs
in DNA to prevent other genetic conditions [40]. BRIP1
functions by maintaining chromosomal stability via its
interaction with the C-terminal in BRCA1 [39, 43]. DNA
damage is evaluated at the G2 cell-cycle checkpoint, and, if
needed, any corrections can be made [40]. Mutations in this
gene hinder its ability to properly check for DNA muta-
tions through messenger RNA (mRNA) involvement [40].
3.1.4 RAD51 recombinase (RAD51)
RAD51 is a gene that codes for the RAD51 protein, which
is responsible for the repair of DSBs in DNA via the HR















































































Fig. 4 HR repair of DSB by BRCA1 and BRCA2. Image taken from Kiyotsugu et al. [119]
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involved with DNA repair. It is located on the long arm of
chromosome 17 at position 22, which is very close to
BRCA1, BRIP1 and RAD51C. RAD51 is known to interact
with BRCA2 to generate a complex that is responsible for
DNA repair [40]. RAD51 regulates BRCA1 and BRCA2 in
HR and localizes BRCA1 in the nuclear foci during the S
and G2 phases of the cell cycle [40]. RAD51 simultane-
ously interacts with BRCA2’s BRC repeats to repair
damaged DNA [44, 45]. The BRC repeat is a set of 35
amino acids (aa) repeated eight times, creating a distinct
motif. This is where RAD51 joins with BRCA2 to repair
DSBs in the DNA into single strand breaks (SSBs) [45].
Mutations in the RAD51 gene interfere with its ability to
localize BRCA2 to repair sites where DSBs exist. This
allows DNA damage to get coded and could potentially
lead to a cancerous state. Mutations that can arise in this
way are called ‘missense mutations’. They affect RAD51’s
ability to bind BRCA2. It was also reported by Woditschka
et al. that overexpression of the RAD51 protein leads to
brain metastases from breast cancer [46]. Another paper
highlights the point that regulation of RAD51 needs to be
exact, as both too much and too little can cause serious
consequences for the body, such as cancer metastasization
and increased resistance to DNA repair [47].
3.1.5 RAD51 Homolog C (RAD51C)
RAD51C belongs to the RAD51 class of genes involved in
the recombinant repair of DNA. It is one of five paralogs of
RAD51 and is responsible for DNA repair via HR [48].
RAD51C is involved with two separate protein complexes,
the RAD51B-RAD51C–RAD51D–XRCC2 complex and
the RAD51C–XRCC2 complex [48]. RAD51C creates a
complex for HR repair with both PALB2 and BRCA2.
RAD51C is located on the long arm of chromosome 17 at
position 22.
3.1.6 BRCA1-Associated RING Domain 1 (BARD1)
BARD1 is a gene that encodes for the human protein
BRCA1-associated RING domain protein 1. BARD1 is
located on the long arm of chromosome 2 at position 35. It
contains a RING finger, as does BRCA1, and when
working together they exhibit ubiquitin ligase activity [49].
The function of BARD1 in the body’s response to breast
cancer remains relatively unknown other than that it is
present in the nucleus with BRCA1 during DNA repair.
However, research by Dr. Kaufmann suggests that it is used
to stabilize the BRCA1 C-terminal complex in order to
repair DSBs [50]. The utilization of BARD1 by BRCA1 in
DNA repair is shown in Fig. 4. BARD1 mutations are
considered a high cancer risk and need further examination,
as their exact function after mutation is relatively
unknown.
3.1.7 Phosphate and Tensin Homolog (PTEN)
PTEN is a gene that encodes for the PTEN protein, a
protein which is found in several different cancers [51–54].
It is found in nearly all tissues in the body and is respon-
sible for tumor suppression [55, 56], apoptosis [57, 58],
angiogenesis [59] and many other functions [60–62].
PTEN is located on the long arm of chromosome 10 at
position 23.3. PTEN is involved in the 1-phosphatidyli-
nositol 3-kinase pathway (PI3K), which is responsible for
cell proliferation and survival. In breast cancer, this results
in PTEN down-regulating PI3K, causing cellular arrest
during the G1 phase of the cell cycle [54]. In general, loss













Fig. 5 HR Repair of DNA with RAD51. RAD51 binds to the 30 end
of DNA, initiating DNA polymerase and repairing the damaged sites.
Image taken from Khanna and Jackson [120]
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3.2 Receptor Markers
Receptor markers are markers that interact with tumor
cells. If a tumor cell binds a corresponding receptor, it is
considered receptor positive, and if it does not, it is con-
sidered negative. When determining whether the cancer is
receptor positive or negative, an oncologist will run a test
where the cells are stained with a dye. Out of the sample of
cells, the dye will stain some cells but not others. The
stained cells carry the receptor being measured. From this,
the oncologist determines what percentage of cells is
stained to assess whether receptor-based treatment will be
successful. The ratio of stained to unstained cells indicates
how many of the cancer cells express the corresponding
receptors. In addition to the proportion of cells stained, the
saturation of the stain is also measured, where a deeper
stain indicates a greater intensity of the receptor. From this
test, the oncologist determines whether the cancer is
receptor positive or negative. This, however, is not an exact
science and will vary based on the oncologist conducting
the test. For example, recovering 15 out of 100 cells with
estrogen receptors may be considered a receptor-negative
result for one lab but a positive result for another. A score
of zero, however, always corresponds to a hormone-re-
ceptor negative result, and in such a case, hormonal therapy
would be ineffective. Below, there is a discussion of the
three receptors for which testing is currently available.
3.2.1 HER2
HER2 is a gene that codes for the HER2 protein, which
manifests as a receptor on breast cells. Over-expression of
this gene results in an increase of HER2 receptors on breast
cells, which in turn causes the breast cells to grow and
divide in a cancerous manner. This HER2-positive form of
breast cancer is very aggressive.
3.2.2 Estrogen Receptor (ER) and Progesterone Receptor
(PR)
ER- and PR-based breast cancers occur when breast cancer
tumor cells contain ERs or PRs. These receptors stimulate
tumor growth in size and number when there is an increase
in the concentration of these hormones in the blood. If a
tumor does not contain estrogen or progesterone receptors,
it is considered to be ER-/PR-. These two hormones are
produced by the ovary and fluctuate in concentration based
on the menstrual cycle.
3.3 MicroRNA
MicroRNAs (miRNAs) are a class of non-coding RNAs
that are 22 nucleotides long whose function is to silence
RNA and affect post-transcriptional regulation of genes
[63–65]. There are over 200 different known miRNAs, and
their expression changes in response to cancer, making
them an excellent candidate for detection and diagnosis of
the disease. It has also been reported that miRNAs exhibit
involvement with tumorigenesis [66–68]. Because of their
relationship with many diseases, including breast cancer,
miRNAs are being studied more and more. New informa-
tion is being revealed on protein expression profiles, new
pathways in disease progression, cellular growth, differ-
entiation, and cellular processes, as well as protein and
RNA silencing as further research on this class of RNAs is
conducted. MiRNAs are formed in the body with the help
of different proteins. DNA is transcribed by messenger
RNA (mRNA), which is then transcribed by RNA poly-
merase II into pri-miRNA [69]. MiRNAs are cleaved from
pre-miRNA precursors by cytoplasmic RNase III Dicer
[64]. Then, two strands are made, and one strand degrades
while the other becomes the mature miRNA [69]. The
effects of miRNA on breast cancer are still not fully
understood, but their expression profiles help with the
diagnosis of breast cancer. MiRNAs can also be easily
accessed from whole blood, not just serum or plasma like
other biomarkers, making them a very powerful diagnostic
tool that requires minimal invasiveness. It has also been
reported that miRNA levels are not biased (varying) based
on whether the condition is in situ, is invasive (IDC, ILC),
has a particular intrinsic subtype (Luminal A, Luminal B,
HER2-enriched and claudin-low) or its HER2 status [70].
Because miRNA levels will be elevated for breast cancer
types, miRNAs are a potentially sensitive and robust
marker for the diagnosis of breast cancer.
3.3.1 Let-7a
The let-7a miRNA belongs to the let-7 family of miRNAs.
This family was one of the first families of miRNAs dis-
covered and is typically poorly expressed or completely
deleted in breast cancer cases [71]. Let-7a belongs to a
class of cells called tumor-initiating cells (TICs), which
can divide asymmetrically as well as undergo self-renewal
[71]. Researchers are currently exploring the mechanisms
involved in up- and down-regulation of let-7a cells in
breast cancer.
3.3.2 MiR-10b
MiR-10b is overexpressed in many metastatic cancers,
including breast cancer, and is known to initiate tumor
invasion in vivo, and cell migration and invasion in vitro
[63, 71]. Ma et al. reported that miR-10b levels were
50-fold higher in metastatic breast cancer cells compared to
non-metastatic breast cancer cells [63]. Interestingly, it was
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reported by Sethi et al. that elevated miR-10b levels caused
breast cancer to metastasize to the brain, but after metas-
tasizing to the brain, miR-10b levels would decrease [72].
Another study showed that levels of miR-10b were found
to be higher in patients with ER- breast cancer compared
to ER? [70]. Additional research on mi-R10b’s function is
required to determine the mechanisms and pathways that
cause it to operate. While it is a key miRNA for breast
cancer, a more concrete understanding of its role in
metastatic cancer and different breast cancer subtypes is
needed before it can be utilized in clinical applications.
3.3.3 MiR-21
MiR-21 is over-expressed in breast cancer cells and is up-
regulated in breast cancer tumor cells compared to normal,
healthy breast cells [71]. Frankel et al. reported that miR-21
regulates the human protein programmed cell death 4
(PDCD4) and has links to the protein p53. Inhibiting levels of
miR-21 increase the levels of PDCD4 3.5-fold [73]. MiR-21
expression also correlates with breast cancer prognosis.
Patients with higher levels of miR-21 have a significantly
worse prognosis compared to patients with lower levels of
miR-21 (85.54 % survival for low expression versus
45.90 % survival for high expression after a five year period)
[65]. It was also observed that patients with ER- breast
cancer expressed higher levels of miR-21 compared to
patients with ER? breast cancer, similar to miR-10b [70].
3.3.4 MiR-155
MiR-155 is found to be up-regulated in breast cancer cells
that have not metastasized [71]. Gasparini et al. show in
their findings that the over-expression of miR-155 in breast
cancer cells inhibits the effects of RAD51 in triple negative
breast cancer. MiR-155 targets the untranslated region of
the 30 in RAD51, resulting in a decreased efficiency of
RAD51 at repairing DSB through HR [74]. This process,
however, is beneficial to ionizing radiation therapy and the
treatment of breast cancer. MiR-155 can be considered a
breast cancer metastasis promoting gene because of its
effect on breast cancer.
3.3.5 MiR-195
MiR-195 is a key miRNA in breast cancer detection. It was
found to be elevated in breast cancer cells compared to
healthy cells and was reported by Heneghan et al. to exhibit
a 19.25-fold change between the two groups [70]. The
same study reported a detection of 85.5 % sensitivity and
100 % specificity in the miRNA as well as an increase in
tumor miRNA expression with later stages of breast
cancer [70].
4 Diagnostic Tests for Breast Cancer Detection
When diagnosing breast cancer, physicians have a large
repertoire of tests at their disposal. Some tests are simple and
require no advanced training or equipment, while other tests
require highly sensitive equipment, large amounts of energy,
and a great deal of time to run. Physicians can draw samples
from a patient for analysis, including tissue biopsies, blood
work or urine work, or they can conduct radiography tests to
imagewhat is happening under the skin. Currently, however,
the use of microfluidics as a diagnostic tool is under-valued.
Microfluidics offer many versatile means of detection, low
energy requirements, and high throughput, and accuracy, as
well as minimal time requirements.
4.1 Mammogram
Mammograms are the most commonly used imaging tech-
nique when looking for breast cancer. They utilize ionizing
radiation at very low energy levels (30 kVp) to generate
images. The purpose of the use of mammograms is to find
tumors before physical lumps can be felt. This is done in an
attempt to diagnose cancer at its early stages so that pre-
ventative measures can be taken, and the chance of mortality
from the disease is lowered. However, mammography has
led to over-diagnosis and treatment of patients who in
actuality never had any breast tumors [75]. One limiting
factor in the use of mammography is the resolution at which
they can generate images. Because they generate images
fromX-rays, they have a finitemaximum resolution,with the
result that tumors under the size of 0.01 nm are not visible on
a mammogram. This, however, does not affect their use
becausemost tumors in early cases of breast cancer are in the
mm range. Mammograms need to be able to differentiate the
tumor tissue in the breasts from the soft tissue, which is very
similar [76]. In a mammogram, there are five distinct char-
acteristics that make up the images: the artifacts, the blur, the
contrast sensitivity, the geometry, and the noise of the image.
Each of these five components is adjusted to generate images
that provide the userwith the best visibility of the inner breast
tissue. The mechanism behind mammograms involves an
X-ray tube made from either molybdenum or molybdenum
and rhodium to produce x-ray radiation. The beam is emitted
from a focal spot between 0.1 and 0.3 mm and through a
filter. The filter decreases any unnecessary exposure of the
patient toX-ray radiation. TheX-rays pass through the breast
tissue and onto a grid, which is used to absorb scattered
radiation and improve the image of the scan. Below the grid
is a digital and film receptor. This receptor takes X-rays and
generates an image of the mammogram scan [76]. The
material for the anode as well as the kV value are selected
based on the size and density of the breast tissue; typical kV
values range between 24 and 32 kV [76]. The higher the kV
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value, the more the x-rays will penetrate the tissue and create
a higher-contrast image. The major limitations of mammo-
grams include the size of the equipment, the energy required
to run the equipment, and the need for a trained individual to
run and interpret the results. While they are a powerful tool,
mammograms require many resources to operate and, as
stated above, can result in over-diagnosis and false positives
as well as false negatives.
4.2 CT Scan
CT scan is another x-ray-based technique to diagnose
breast cancer. Like mammography, it provides no insight
into the genetics involved with the cancer or the hormone
receptor status. It is merely used to detect signs of breast
cancer. CT scan has five specific image characteristics:
blurring and detail, visual noise, artifacts, tomographic
slices, and contrast sensitivity [77]. CT scan differs from
mammograms in requiring less involvement of a trained
technician and providing much faster results [77]. How-
ever, one drawback of CT scan is the need for both ionizing
radiation and intravenous contrast material for image
generation. The contrast material can have adverse effects
on the patient and, in rare circumstances, can result in
death. A CT scan works by rotating the unit around a
patient while moving up or down over the region to be
scanned. The scanning methods for a CT scan include step
and scan, and helical or spiral scanning. Step and scan
works by rotating around one slice of the body, then
moving to another slice, and rotating again. Helical or
spiral scanning works by rotating around the body while
the body is moved up or down. In the scan, three values are
of interest: the pitch, the width, and the distance per rev-
olution. The width corresponds to the width of the beam,
which determines how wide the scanning area will be. The
distance per revolution is how far the body (or machine) is
moved per revolution, and the pitch is the distance moved
per revolution per width. A faster pitch results in a quicker
scan, but the resolution might not be as high [77]. In
addition to single beam scans, a multiple beam scan can
also be performed. This allows the scan to run faster, and
data are overlapped to generate complete images of the
scan area. Like mammography equipment, CT scanners are
very bulky and require a great deal of resources to operate.
While powerful, CT scanning cannot be used in the field to
diagnose breast cancer.
4.3 MRI
MRI is a powerful imaging technique that utilizes magnetic
fields and radio frequencies to generate images of breast
tissue. The MR image is dependent on a few factors,
including the proton density of the tissue, longitudinal and
transverse relaxation times of the tissue, vascular flow of
the fluid, perfusion of the fluid, diffusion of the fluid, and
chemical spectroscopy [77]. The proton density of the
tissue relates to image generation, so tissue with higher
proton densities will show up brighter and with more
intensity than a tissue with lower density. The longitudinal
and transverse relaxation times pertain to how long it takes
the tissue to go from a magnetized state to a normal state
and vice versa [77]. These two times are denoted T1 and
T2. This produces contrast between images because heal-
thy and tumorous tissues differ in their relaxation times.
Vascular flow, perfusion, and diffusion of the blood create
contrast within the image to help distinguish flowing
regions from tissue regions as well as sediments or artifacts
within the flow of fluids. Lastly, the spectroscopic chemical
fluid adds additional contrast to help distinguish different
features within the image from one another. These factors
combine to emit a radio frequency that generates the
image. The images are generated when a patient is placed
inside the magnetic field of the machine and the magnetic
nuclei within their tissues emit a radio frequency [77].
Image generation and variation is dependent on the tissue
and fluid characteristics. Therefore, in a breast MRI, a
tumor would show up differently from normal healthy
tissue because of its different characteristics. When the
image is being generated, the tissue goes through a series
of magnetizations. Similar to a pulse occurring over a
period of time, the tissue is subjected to a series of mag-
netizations over a period of time, resulting in different
intensities of radio frequency emission [77]. While this is a
powerful tool, MRI is very costly to operate, requires a
great deal of energy, is not mobile in anyway, and is
subject to the interpretation of oncologists. While they are
highly trained individuals, there is always the chance for
human error, and false negatives and positives in the
images.
4.4 Ultrasound
Ultrasound imaging is a much more basic tool compared to
the other tools discussed. It employs the use of a transducer
to emit ultrasonic sound waves into the tissue. This method
has no adverse effects on the patient and can provide
images immediately. It can be portable, is easy to operate
and can create detailed images; however, it does not pro-
vide definitive proof of a tumor, as the images produced
could represent calcified stones.
4.5 PCR
Polymerase chain reaction (PCR) is one of the most com-
monly used lab techniques for to analyze DNA samples.
This technique can be used for DNA sequencing [78],
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analyzing the functionality of genes [79, 80], and diag-
nosing hereditary cases of breast cancer [52, 81–83]. To
amplify DNA using PCR, the following are required: two
3’ primers for the strands of DNA, DNA polymerase to
synthesize strands of DNA, buffer solutions, and cations,
and deoxynucleotide triphosphate. PCR works under the
principal of heat cycling, where 30-40 heat cycles are used
to denature and rebuild the DNA sequence. The method-
ology for PCR is as follows: the mixture is heated to
96–98 C for 20–30 s to denature the bonds between the
DNA, leaving two single strands. Then the annealing step
occurs in which the reaction temperature drops to 55 C for
20 s. This step needs to take into account the recommended
temperature for hybridization of the primer strands. Once
annealing begins, the temperature rises to 72 C to begin
the extension step of the DNA. These denaturing, anneal-
ing, and extension steps are repeated for 35 cycles. After
the 35th cycle, the extension step is maintained for 5 min to
ensure that the single strand of DNA has become a double
strand. Then a cool down step is performed, where the
temperature drops to 15 C to hold the sample before it is
analyzed [84]. PCR can also be used for RNA analysis.
This process is called reverse transcription PCR (RT-PCR).
Similar to the methods used for DNA, RT-PCR utilizes
heat cycles to reverse transcribe RNA strands. The reagents
required are slightly different from those for DNA. The
materials required for this process can be seen in ref. 83,
and the process is as follows: the reaction mixture is
incubated at 23 C for 10 min, then at 42 C for
30-60 min. The mixture is then heated for 5-10 min at
95 C in a water bath, then immediately put into an ice bath
[84]. The samples are then analyzed. Early detection of
breast cancer using PCR has been well-documented [85–
88] and provides insight into the gene and receptor
involvement of breast cancer patients. PCR can also be
used to identify miRNAs that may present themselves
when a patient has breast cancer [89–93]. Figure 6 depicts
how RT-PCR can be used to detect miRNA samples. While
PCR is a powerful tool, it does have limitations. Because of
the need to create DNA/RNA strands, there is a chance that
an error or mutation can arise during the process, leading to
false positive or negative results. Additionally, PCR, like
most medical equipment, requires a great deal of power to
run, as well as a trained individual to interpret the results.
4.6 Immunohistochemistry (IHC)
IHC is a method by which antibodies are detected in the
body. IHC is a staining technique used to identify tumor
cells in a tissue sample and is often combined with optical-
based techniques like FRET or BRET. IHC allows
researchers to gather samples and examine them to physi-
cally see whether breast cancer is present, without the use
of expensive equipment such as MRIs and CT scanners.
IHC requires tissue collection, fixation, and sectioning.
Collection is done via biopsy or sample drawing. Fixation
often involves the use of paraformaldehyde to prevent
tissue decay, as well as staining and washing to highlight
target tumor cells that are of interest. IHC is an excellent
technique to determine the receptor status of a tumor [91,
94, 95]. The major limitation of IHC is the need for a lab
environment and microscope to analyze the sample. IHC
also requires tissue staining reagents that may be costly.
Lastly, IHC requires a trained individual to determine what
is actually present on the sample slides. While IHC does
not have heavy energy requirements and is easy to conduct
in a lab environment, it is not an ideal solution for early
breast cancer detection.
5 Microfluidics
Microfluidics is emerging as a novel platform for con-
ducting complex, expensive, time-dense, and technically
difficult lab procedures on a microchip that overcomes all
of these drawbacks [96–99]. Because of its scaled-down
size, a microfluidics platform is able to complete complex
tasks very quickly with little reagent involvement. This
makes it an ideal platform for diagnostic testing because of
its high throughput, low time requirement, and high accu-
racy characteristics [100]. With regards to the reagents, due
to the size of the platform, any fluid flowing in a
microfluidics chip undergoes laminar flow. This flow can
be adjusted with high accuracy, making it possible to
control the flow of the fluid to meet any specific require-













Fig. 6 Schematic of RT-PCR in detection of miRNA. Stem-Loop RT
primers bind to the 30 end of miRNA and reverse transcribe the
molecule. Then, traditional PCR transcribes the 50 end. Image taken
from Calfu et al. [121]
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microfluidics tests are in the mL range (equivalent to a drop
of blood), and the only drawback is that it cannot identify
markers that do not appear in bodily fluid. Microfluidics
chips are made on a silicon wafer in a manner similar to
semiconductor chips [100]. They can be specified to meet
any demand, and their limitation is fluid flow through the
chip. Because of the tight packing of the chip, the flow of a
liquid is hindered by high pressures in the system and
hydrogen bond forces that interfere with laminar flow.
Researchers got around this issue by ionizing fluid as it
flows through the chamber [100]. A full review of
microfluidics and the science behind it is presented here
[101].
A microfluidic chip utilizes the basic physical properties
of the micron scale: diffusion is used to transport fluid
constituents where they need to be, pressure is used to
move volumes of liquid into chambers and electro-resis-
tance [101–103] and fluorescence [104, 105] are used to
analyze samples in the fluid. Microfluidics platforms are
currently being used to detect genetic mutations that cor-
respond to breast cancer, including DNA and miRNA
mutations [106–111]. Due to their high throughput and low
time requirements, these platforms are able to analyze
more sample volume in a shorter amount of time than
traditional detection methods. As a result, microfluidics
chips that can analyze multiple proteins in blood have been
developed to save time and resources. Fan et al. developed
a microfluidics chip that can sample a large range of pro-
teins within 10 min after sample collection [112]. This
greatly reduces the stress on resources and time, allowing
more time to run tests and less time to wait for them.
Microfluidics platforms can also be combined with
nanoparticles such as quantum dots (a crystal material used
to enhance resolution in sample images). This allows for
even greater resolution with a short time requirement for
tests [113]. A report conducted by Mei Hu et al. utilized
microfluidics chips and QDs to measure cancer biomarkers
at a detection limit of 250 fM [113]. Another report by
Amily Fang-ju Jou et al. discusses using QDs and FRET to
detect miRNAs involved with prostate cancer [114]. While
this miRNA is not involved with breast cancer, similar
techniques can be utilized to detect the miRNAs involved
with breast cancer. Jou’s team developed QDs with cad-
mium selenide (CdSe) and zinc sulfide (ZnS) and com-
bined this with FRET quencher-functionalized nucleic
acids, meaning that excitation occurs in the presence of a
nucleic acid. Using this technology, they obtained optical
detection sensitivity in the pico-molar range [114].
Microfluidic chips have reached the point where they
can separate blood from plasma and conduct tests within a
single chip using magnetic beads and other nanoparticles
[115]. There have been further advancements with tumor
cell detection and separation using microfluidics as well
[102, 116]. Because of their size, ease of use, and ability to
save time, money, and resources, microfluidics can quickly
surpass other detection methods when it comes to diag-
nosing breast cancer. The only drawback they currently
face is the lack of a microfluidics system available that can
conduct every single laboratory process on a single chip.
There have been chips that are able to conduct multiple
processes, such as separation and detection, but no chip
currently analyzes and displays the information on a read
out that anyone can interpret. This is the next logical step to
allow microfluidics technology to eclipse mammograms,
CT scanners, and MRI machines as the go-to detection tool
for breast cancer. With detection limits getting lower and
lower, it becomes possible to detect cancer before it enters
its later stages and save patient lives using this technology.
6 Future Recommendations
With limited resources and infrastructure, and viewing
breast cancer as a global disease rather than one that is only
endemic to developing nations, practitioners must have the
ability to use diagnostic equipment globally with low
energy requirements. Microfluidics-based lab-on-a-chip
technology needs to develop the capacity to conduct an
entire lab operation on one chip, without the use of any
other equipment. The markers needed for detecting breast
cancer are available through miRNAs, oncogenes, and
proteins. The microfluidics platform now needs to utilize
these markers and display the results for any user to
understand. Future research will need to be conducted to
further understand miRNAs and how they form with
respect to breast cancer, typical levels for healthy and
diseased patients, and how these levels change with respect
to disease progression. This knowledge can then be applied
to a microfluidics platform and used to diagnose breast
cancer with 100 % certainty. It may also be possible to
predict the onset of cancer by monitoring these biomarkers
in the body and attempt to reregulate them when they enter
some altered state. To achieve this utopian diagnostic
technology, first and foremost, studies will need to be
conducted on how miRNA expression in the body is altered
with respect to mutations that lead to cancer. This funda-
mental knowledge will pave a path toward better under-
standing of the role of miRNAs in cancer. Based on present
knowledge, an educated selection can be made of specific
miRNAs that play meaningful roles in breast cancer. Once
a set of miRNAs has been developed, testing can begin to
determine how expression values change with the onset of
breast cancer. However, to make this a more robust and
powerful test, oncogenes and proteins should also be
incorporated, as these all play roles during the development
of breast cancer and can support the diagnostic power of
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the test. From the knowledge gained from this study,
expression levels of miRNAs, oncogenes, and proteins can
be used to predict breast cancer onset, and steps can be
taken to prevent the disease from becoming terminal.
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